Isomorphic Labs Set to Begin Clinical Trials for AI-Designed Drugs This Year

Isomorphic Labs aims to start testing its first AI-designed drugs by the end of 2023, as highlighted by CEO Demis Hassabis at the World Economic Forum. AI's potential for faster and cheaper drug development is significant, with over 460 startups in the field. Isomorphic has also partnered with Eli Lilly and Novartis for AI research. While AI accelerates drug discovery, traditional lab tests and trials remain crucial.